Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow ... Adjusted earnings are expected to come in at $4.02 per share. Vertex Pharmaceuticals Total Revenue ...

VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can potentially garner $4 billion in annual ...

Vertex Pharmaceuticals Incorporated VRTX announced that the FDA has approved its oral, non-opioid, highly selective NaV1.8 pain signal inhibitor, suzetrigine, for the treatment of adults with ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...

In a report released on February 4, Bank of America Securities also maintained a Buy rating on the stock with a $540.00 price target. VRTX market cap is currently $120.9B and has a P/E ratio of ...

U.S.-based Vertex Pharmaceuticals (VRTX) has secured approval from the ... they provide a safer alternative to opioids, with fewer side effects, while reducing reliance on addictive opioids.

Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon ... Adjusted earnings are expected to come in at $4.02 per share. Vertex Pharmaceuticals Total Revenue ...

VRTX Price Action: Vertex shares were up 4.96% at $460.15 at the time of writing, according to Benzinga pro.